New open access journal highlights methods and clinical trial results

The first issue of Elsevier's new open access journal Contemporary Clinical Trials Communications features a new method to make cancer clinical trials more effective, a better way of determining whether a trial was successful and a dashboard that helps patients enroll in trials. The journal is a spin-off of the well-established title Contemporary Clinical Trials.

There are many ways to carry out a clinical trial. Researchers need to think about the number of patients to enroll, the type of treatments to give and their frequency, among many other factors. Contemporary Clinical Trials Communications publishes methodology and statistics that answer these questions, helping researchers build on each other's work and design better trials.

For example, in the first issue of the journal, which is now available on ScienceDirect, researchers from Genentech Inc. and the Deerfield Institute describe a new trial design that helps researchers take into account delayed effects of immune-oncology treatments.

"I trust that the readers will find the journal a valuable source of recent advancements in clinical trials," said Dr. Zhezhen Jin, co-Editor-in-Chief of Contemporary Clinical Trials Communications and Professor of Biostatistics at Columbia University in New York. He also explained that this knowledge can "facilitate the design, conduct and analysis of their trials."

The journal also aims to tackle the problem of publication bias towards positive results by making all trial data open access.

"A major objective of the journal is to reduce publication bias, which is a major issue in the field of clinical trials," said Dr. Zheng Su, co-Editor-in-Chief of Contemporary Clinical Trials Communications and VP at the Deerfield Institute in New York.

There are two main approaches to clinical trials: randomized and non-randomized. In randomized trials, the participants do not know whether they are receiving the treatment or a placebo. In non-randomized trials, the participants are often all given the treatment. Many clinical trials journals only publish randomized trials, but Contemporary Clinical Trials Communications will publish both.

"There are several existing clinical trials journals that either give preferential treatment to positive trial results due to their perceived higher significance, or focus only on randomized trials," added Dr. Jin. "In contrast, Contemporary Clinical Trials Communications provides a platform for trialists around the world to share their knowledge on all aspects of clinical trials. We're making scientifically valid and technically sound original research findings freely accessible regardless of their perceived importance or impact."

Contemporary Clinical Trials Communications is now open for submissions. The first issue is published on ScienceDirect.

About Contemporary Clinical Trials Communications
Contemporary Clinical Trials Communications is an international, peer-reviewed, open access journal that publishes articles on all aspects of clinical trials, including design, conduct, analysis, regulation and ethics. Articles appeal to a wide range of disciplines. Contemporary Clinical Trials Communications strives to increase the transparency of medical research and reduce publication bias by publishing scientifically valid original research findings, irrespective of their perceived importance, significance or impact.

About Elsevier
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions - among them ScienceDirect, Scopus, Elsevier Research Intelligence and ClinicalKey - and publishes over 2,500 journals, including The Lancet and Cell, and more than 33,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group plc, a world-leading provider of information solutions for professional customers across industries.

Most Popular Now

FDA approves drug to treat ALS

The U.S. Food and Drug Administration today approved Radicava (edaravone) to treat patients with amyotrophic lateral sclerosis (ALS), commonly referred to as Lou Gehrig's...

Read more

FDA approves first cancer treatment for any solid …

The U.S. Food and Drug Administration today granted accelerated approval to a treatment for patients whose cancers have a specific genetic feature (biomarker). This is th...

Read more

Sanofi and Regeneron announce FDA Approval of Kevz…

Sanofi and Regeneron Pharmaceuticals, Inc. have announced the U.S. Food and Drug Administration (FDA) approval of Kevzara® (sarilumab) for the treatment of adult patients...

Read more

AstraZeneca marks a key milestone with the ‘toppin…

AstraZeneca marks a key milestone in its successful move to Cambridge, UK, with the 'topping out' of its new, state-of-the-art, strategic R&D centre and global corporate ...

Read more

FDA approves first treatment for a form of Batten …

The U.S. Food and Drug Administration today approved Brineura (cerliponase alfa) as a treatment for a specific form of Batten disease. Brineura is the first FDA-approved ...

Read more

Abbott announces CE Mark and first use of the worl…

Abbott (NYSE: ABT) today announced CE Mark and first use of the new Confirm RxTM Insertable Cardiac Monitor (ICM), the world's first smartphone compatible ICM that will h...

Read more

Imfinzi significantly reduces the risk of disease …

AstraZeneca and MedImmune, its global biologics research and development arm, today announced positive results for the Phase III PACIFIC trial, a randomised, double-blind...

Read more

Antibiotic doxycycline may offer hope for treatmen…

A study published in the journal Scientific Reports suggests that doxycycline, an antibiotic used for over half a century against bacterial infections, can be prescribed ...

Read more

Novartis exercises exclusive option agreement with…

Novartis announced today that it has notified Conatus Pharmaceuticals Inc., of its exercise of the option to an exclusive license for the global development and commercia...

Read more

England's Cancer Drugs Fund 'failed to deliver mea…

Analysis of the drugs that were approved for use by the NHS Cancer Drugs Fund (CDF) in England has shown that the fund was not good value for patients and society and may...

Read more

High levels of exercise linked to nine years of le…

Despite their best efforts, no scientist has ever come close to stopping humans from aging. Even anti-aging creams can't stop Old Father Time. But new research from Brigh...

Read more

Vitamin A deficiency is detrimental to blood stem …

Many specialized cells, such as in the skin, gut or blood, have a lifespan of only a few days. Therefore, steady replenishment of these cells is indispensable. They arise...

Read more

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]